{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:12:42Z","timestamp":1787065962500,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.neuropharm.2017.08.032","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:32:20Z","timestamp":1504139540000},"page":"97-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents"],"prefix":"10.1016","volume":"126","author":[{"given":"Nobuhito","family":"Murai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Kiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Sekizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonari","family":"Watabiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.08.032_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.thromres.2007.08.014","article-title":"Gene expression profiling for the identification of G-protein coupled receptors in human platelets","volume":"122","author":"Amisten","year":"2008","journal-title":"Thromb. Res."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/j.pain.0000000000000753","article-title":"Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles","volume":"158","author":"Baron","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","article-title":"A\u00a0peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man","volume":"33","author":"Bennett","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1601-183X.2012.00840.x","article-title":"LPA5 receptor plays a role in pain sensitivity, emotional exploration and reversal learning","volume":"11","author":"Callaerts-Vegh","year":"2012","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib6","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn2055","article-title":"Regulatory mechanisms of AMPA receptors in synaptic plasticity","volume":"8","author":"Derkach","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0304-3959(88)90026-7","article-title":"A\u00a0new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia","volume":"32","author":"Hargreaves","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(80)90515-4","article-title":"Intrathecal morphine in mice: a new technique","volume":"67","author":"Hylden","year":"1980","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nm1060","article-title":"Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling","volume":"10","author":"Inoue","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.neuropharm.2010.12.005","article-title":"Involvement of spinal phosphorylation cascade of Tyr1472-NR2B, Thr286-CaMKII, and Ser831-GluR1 in neuropathic pain","volume":"60","author":"Katano","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/jpet.105.098848","article-title":"Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes","volume":"318","author":"Kotarsky","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib13","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1016\/j.bmcl.2012.06.057","article-title":"Selective non-lipid modulator of LPA5 activity in human platelets","volume":"22","author":"Kozian","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ejpain.2010.10.003","article-title":"Mechanisms of dynamic mechanical allodynia and dysesthesia in patients with peripheral and central neuropathic pain","volume":"15","author":"Landerholm","year":"2011","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0378-1119(01)00651-5","article-title":"Discovery and mapping of ten novel G protein-coupled receptor genes","volume":"275","author":"Lee","year":"2001","journal-title":"Gene"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib16","doi-asserted-by":"crossref","first-page":"23589","DOI":"10.1074\/jbc.M603670200","article-title":"GPR92 as a new G12\/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5","volume":"281","author":"Lee","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib17","doi-asserted-by":"crossref","first-page":"17608","DOI":"10.1074\/jbc.M111.330183","article-title":"Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain","volume":"287","author":"Lin","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"issue":"29","key":"10.1016\/j.neuropharm.2017.08.032_bib18","article-title":"An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model","volume":"9","author":"Ma","year":"2013","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/jpet.109.164830","article-title":"Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain","volume":"333","author":"Ma","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0006-8993(01)02069-8","article-title":"Characterization of the glutamatergic system for induction and maintenance of allodynia","volume":"895","author":"Minami","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1476-5381.1994.tb13139.x","article-title":"Characterization of EP-receptor subtypes involved in allodynia and hyperalgesia induced by intrathecal administration of prostaglandin E2 to mice","volume":"112","author":"Minami","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0304-3959(92)90166-9","article-title":"Allodynia evoked by intrathecal administration of prostaglandin F2\u03b1 to conscious mice","volume":"50","author":"Minami","year":"1992","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0304-3959(94)90226-7","article-title":"Allodynia evoked by intrathecal administration of prostaglandin E2 to conscious mice","volume":"57","author":"Minami","year":"1994","journal-title":"Pain"},{"issue":"5322","key":"10.1016\/j.neuropharm.2017.08.032_bib24","article-title":"pEF-BOS, a powerful mammalian expression vector","volume":"18","author":"Mizushima","year":"1990","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.113.208686","article-title":"AS1069562, the (+)-isomer of indeloxazine, exerts analgesic effects in a rat model of neuropathic pain with unique characteristics in spinal monoamine turnover","volume":"348","author":"Murai","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pbb.2015.11.008","article-title":"Spontaneous and evoked pain-associated behaviors in a rat model of neuropathic pain respond differently to drugs with different mechanisms of action","volume":"141","author":"Murai","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1179\/1743132815Y.0000000007","article-title":"AS1069562, the (+)-isomer of indeloxazine, exerts analgesic effects in rat models of nociceptive pain","volume":"37","author":"Murai","year":"2015","journal-title":"Neurol. Res."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2014.03.038","article-title":"Antinociceptive effects of AS1069562, the (+)-isomer of indeloxazine, on spinal hypersensitivity induced by intrathecal injection of prostaglandin in mice: comparison with duloxetine and amitriptyline","volume":"733","author":"Murai","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1471-4159.2003.01840.x","article-title":"Functional characterization of prostaglandin F2\u03b1 receptor in the spinal cord for tactile pain (allodynia)","volume":"86","author":"Muratani","year":"2003","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib30","doi-asserted-by":"crossref","first-page":"21054","DOI":"10.1074\/jbc.M708908200","article-title":"Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92","volume":"283","author":"Oh","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"issue":"67","key":"10.1016\/j.neuropharm.2017.08.032_bib31","article-title":"Role of spinal cord alpha-amino-3-hydroxy-5-methy-4-isoxazolepropionic acid receptors in complete Freund's adjuvant-induced inflammatory pain","volume":"4","author":"Park","year":"2008","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejphar.2010.02.025","article-title":"Spinal mechanism of standard analgesics: evaluation using mouse models of allodynia","volume":"634","author":"Tsukamoto","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/cbic.201500559","article-title":"Modulation of hexadecyl-LPA-mediated activation of mast cells and microglia by a chemical probe of LPA5","volume":"17","author":"Von Haeften","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib34","doi-asserted-by":"crossref","first-page":"17304","DOI":"10.1074\/jbc.M109.003194","article-title":"Unique ligand selectivity of the GPR92\/LPA5 lysophosphatidate receptor indicates role in human platelet activation","volume":"284","author":"Williams","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib35","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1126\/science.288.5472.1765","article-title":"Neuronal plasticity: increasing the gain in pain","volume":"288","author":"Woolf","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.08.032_bib36","doi-asserted-by":"crossref","first-page":"7445","DOI":"10.1523\/JNEUROSCI.1812-08.2008","article-title":"Presynaptic and postsynaptic amplifications of neuropathic pain in the anterior cingulate cortex","volume":"28","author":"Xu","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.032_bib37","doi-asserted-by":"crossref","first-page":"12328","DOI":"10.1074\/jbc.M806516200","article-title":"Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay","volume":"284","author":"Yin","year":"2009","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:59:46Z","timestamp":1719403186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817304112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":37,"alternative-id":["S0028390817304112"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.032","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}